Retension Pharmaceuticals, Inc. (NASDAQ: RTSN), a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular diseases, announced the pricing of its upsized initial public offering of 3,750,000 shares of common stock at $12 per share. The offering is expected to generate gross proceeds of $45 million before underwriting discounts, commissions and other offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 562,500 shares to cover over-allotments.
Retension shares were expected to begin trading on the Nasdaq Capital Market on October 9, 2026, under the ticker symbol RTSN, with the offering scheduled to close on or about October 13, subject to customary closing conditions. The successful pricing of the upsized IPO signals strong investor demand for the company’s pipeline, which centers on RTN-001, a clinical candidate in development for patients with uncontrolled and resistant hypertension.
The net proceeds, together with existing cash and cash equivalents, will be used primarily to complete a Phase 2b clinical trial of RTN-001 for uncontrolled hypertension and to prepare for, support and advance a planned Phase 3 trial. Remaining funds will be allocated to general corporate purposes and operating expenses. This funding is critical for Retension as it transitions from a clinical-stage company to a potential commercial player in the cardiovascular space. Uncontrolled hypertension affects millions of patients worldwide and is a leading risk factor for heart disease, stroke and kidney failure, making new treatment options a significant public health priority.
Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are serving as joint bookrunning managers for the offering, with Titan Partners acting as lead manager. The involvement of these reputable financial institutions lends credibility to the offering and may help attract further institutional interest.
For investors seeking detailed market research on Retension, a comprehensive profile is available through Retension (NASDAQ: RTSN). The full press release can be accessed at https://ibn.fm/uko0m, and more information about the company is available at https://www.retensionpharmaceuticals.com/.
The announcement was distributed by InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and a full array of tailored corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
